Anti-glomerular basement membrane disease is a rare disease. In its classical presentation it associates rapidly progressive glomerulonephritis and diffuse alveolar hemorrhage, linked to the presence of antibodies targeting type IV collagen in the glomerular and alveolar basal membrane. Anti-GBM disease warrants prompt medical management to limit permanent kidney damage and mortality. Treatment includes plasma exchanges to quickly remove pathogenic antibodies and immunosuppressants to stop their production. This article reviews the pathogenesis and current treatments.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.53738/REVMED.2023.19.821.680 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!